Giovanni Addolorato

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3124541/publications.pdf

Version: 2024-02-01

227 papers

14,368 citations

28274 55 h-index 24258 110 g-index

237 all docs

237 docs citations

times ranked

237

11689 citing authors

#	Article	IF	Citations
1	Limited Access to Emotion Regulation Strategies Mediates the Association Between Positive Urgency and Sustained Binge Drinking in Patients with Alcohol Use Disorder. International Journal of Mental Health and Addiction, 2023, 21, 3549-3562.	7.4	6
2	Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA). Digestive Diseases and Sciences, 2022, 67, 1975-1986.	2.3	7
3	Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study. American Journal of Transplantation, 2022, 22, 1191-1200.	4.7	29
4	Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy. Seminars in Liver Disease, 2022, 42, 138-150.	3.6	9
5	The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990–2019: Findings from the Global Burden of Disease Study 2019. Lancet Regional Health - Europe, The, 2022, 16, 100341.	5.6	70
6	Echocardiographic markers of early alcoholic cardiomyopathy: Six-month longitudinal study in heavy drinking patients. European Journal of Internal Medicine, 2022, 101, 76-85.	2.2	6
7	Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?. European Journal of Internal Medicine, 2022, , .	2.2	4
8	Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology, 2022, 36, 1136-1145.	4.0	5
9	The gut–brain axis in irritable bowel syndrome and inflammatory bowel disease. Digestive and Liver Disease, 2021, 53, 298-305.	0.9	37
10	Effect of Alcohol Combined With High Fat Diet: Two Wrongs Don't Make a Right but They Could Make a Good Excuse. Alcohol and Alcoholism, 2021, 56, 348-350.	1.6	3
11	Transcranial Magnetic Stimulation: A review about its efficacy in the treatment of alcohol, tobacco and cocaine addiction. Addictive Behaviors, 2021, 114, 106760.	3.0	38
12	Delta-Procalcitonin and Vitamin D Can Predict Mortality of Internal Medicine Patients with Microbiological Identified Sepsis. Medicina (Lithuania), 2021, 57, 331.	2.0	6
13	More on SARS-CoV-2 Infection after Vaccination in Health Care Workers. New England Journal of Medicine, 2021, 385, e8.	27.0	3
14	Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A metaâ€regression analysis to develop an enrichment strategy. Alcoholism: Clinical and Experimental Research, 2021, 45, 1722-1734.	2.4	12
15	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. International Journal of Clinical Practice, 2021, 75, e14755.	1.7	13
16	Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study. European Neuropsychopharmacology, 2021, 52, 18-30.	0.7	13
17	Signs of Dissociation and Symptoms of Post-Traumatic Stress Disorder in Inflammatory Bowel Disease: A Case-Control Study. Digestive Diseases, 2021, , .	1.9	3
18	Alcohol-related Liver Disease and sepsis. European Review for Medical and Pharmacological Sciences, 2021, 25, 4563-4569.	0.7	1

#	Article	IF	CITATIONS
19	Takotsubo Syndrome and Inflammatory Bowel Diseases: Does a Link Exist?. Digestive Diseases, 2020, 38, 204-210.	1.9	5
20	Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows. Neurotherapeutics, 2020, 17, 127-141.	4.4	14
21	Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects. Expert Opinion on Drug Safety, 2020, 19, 159-166.	2.4	17
22	Make Mission Impossible Feasible: The Experience of a Multidisciplinary Team Providing Treatment for Alcohol Use Disorder to Homeless Individuals. Alcohol and Alcoholism, 2020, 55, 547-553.	1.6	6
23	Assessment of neurological manifestations in hospitalized patients with COVIDâ€19. European Journal of Neurology, 2020, 27, 2322-2328.	3.3	36
24	Wernicke's Encephalopathy in Alcohol Use Disorder Patients after Liver Transplantation: A Case Series and Review of Literature. Journal of Clinical Medicine, 2020, 9, 3809.	2.4	3
25	COVID-19 and intestinal inflammation: Role of fecal calprotectin. Digestive and Liver Disease, 2020, 52, 1231-1233.	0.9	40
26	Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Journal of the American College of Cardiology, 2020, 76, 2982-3021.	2.8	4,468
27	Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcoholâ€associated liver disease. Liver International, 2020, 40, 878-888.	3.9	68
28	Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2020, 52, 374-391.	0.9	29
29	The use of procalcitonin for the management of sepsis in Internal Medicine wards: current evidence. Panminerva Medica, 2020, 62, 54-62.	0.8	7
30	Alcohol and Cardiovascular Function. , 2020, , 793-801.		0
31	Alcohol and Cardiovascular Function. , 2020, , 1-9.		0
32	Repetitive transcranial magnetic stimulation: Re-wiring the alcoholic human brain. Alcohol, 2019, 74, 113-124.	1.7	10
33	Predictors of mortality of bloodstream infections among internal medicine patients: Mind the complexity of the septic population!. European Journal of Internal Medicine, 2019, 68, e22-e23.	2.2	4
34	Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: A consensus paper on the present state of the science and the road ahead. Neuroscience and Biobehavioral Reviews, 2019, 104, 118-140.	6.1	198
35	Zolpidem high-dose abuse: what about the liver? Results from a series of 107 patients. Expert Opinion on Drug Safety, 2019, 18, 753-758.	2.4	7
36	May nutritional status worsen during hospital stay? A sub-group analysis from a cross-sectional study. Internal and Emergency Medicine, 2019, 14, 51-57.	2.0	21

#	Article	IF	CITATIONS
37	Management of celiac disease in daily clinical practice: do not forget depression!. European Journal of Internal Medicine, 2019, 62, e17.	2.2	3
38	Madelung's disease and acute alcoholic hepatitis: case report and review of literature. European Review for Medical and Pharmacological Sciences, 2019, 23, 6272-6276.	0.7	5
39	Does high-dose benzodiazepine abuse really produce liver toxicity? Results from a series of 201 benzodiazepine monoabusers. Expert Opinion on Drug Safety, 2018, 17, 451-456.	2.4	8
40	Alcohol addiction - the safety of available approved treatment options. Expert Opinion on Drug Safety, 2018, 17, 169-177.	2.4	33
41	Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry,the, 2018, 5, 957-960.	7.4	94
42	Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohola€Preferring Rats. Alcoholism: Clinical and Experimental Research, 2018, 42, 2313-2325.	2.4	29
43	Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. Frontiers in Psychiatry, 2018, 9, 474.	2.6	19
44	Liver Transplantation in Patients with Alcoholic Liver Disease: A Retrospective Study. Alcohol and Alcoholism, 2018, 53, 151-156.	1.6	10
45	Risk, prevalence, and impact of hospital malnutrition in a Tertiary Care Referral University Hospital: a cross-sectional study. Internal and Emergency Medicine, 2018, 13, 689-697.	2.0	25
46	Efficacy and safety of sodium oxybate in alcoholâ€dependent patients with a very high drinking risk level. Addiction Biology, 2018, 23, 969-986.	2.6	59
47	Binge Drinking among adolescents is related to the development of Alcohol Use Disorders: results from a Cross-Sectional Study. Scientific Reports, 2018, 8, 12624.	3.3	50
48	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. Frontiers in Psychiatry, 2018, 9, 708.	2.6	47
49	Addiction disorders: a need for change. Proposal for a new management. Position paper of SIA, Italian Society on Alcohol. Minerva Medica, 2018, 109, 369-385.	0.9	43
50	Alcoholic cardiomyopathy: What is known and what is not known. European Journal of Internal Medicine, 2017, 43, 1-5.	2.2	74
51	Deep Transcranial Magnetic Stimulation of the Dorsolateral Prefrontal Cortex in Alcohol Use Disorder Patients: Effects on Dopamine Transporter Availability and Alcohol Intake. European Neuropsychopharmacology, 2017, 27, 450-461.	0.7	62
52	Determinants of Quality of Life in High-Dose Benzodiazepine Misusers. International Journal of Environmental Research and Public Health, 2017, 14, 38.	2.6	29
53	Dental health in patients affected by alcohol use disorders: a cross-sectional study. European Review for Medical and Pharmacological Sciences, 2017, 21, 5021-5027.	0.7	7
54	Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. World Journal of Hepatology, 2017, 9, 1322-1331.	2.0	2

#	Article	IF	CITATIONS
55	A Brief Up-Date of the Use of Sodium Oxybate for the Treatment of Alcohol Use Disorder. International Journal of Environmental Research and Public Health, 2016, 13, 290.	2.6	25
56	Liver Transplantation for Alcoholic Liver Disease. Transplantation, 2016, 100, 981-987.	1.0	65
57	Treatment of alcohol use disorders in patients with alcoholic liver disease. Journal of Hepatology, 2016, 65, 618-630.	3.7	156
58	High prevalence of constipation and reduced quality of life in opioid-dependent patients treated with opioid substitution treatments. Expert Opinion on Pharmacotherapy, 2016, 17, 2135-2141.	1.8	17
59	Reply to "Treatment of alcohol use disorders in patients with liver disease― Journal of Hepatology, 2016, 65, 1271.	3.7	1
60	Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series. Journal of Psychopharmacology, 2016, 30, 402-409.	4.0	7
61	Targeting the GABAB Receptor for the Treatment of Alcohol Use Disorder. , 2016, , 287-307.		6
62	Human Rickettsia aeschlimannii infection: first case with acute hepatitis and review of the literature. European Review for Medical and Pharmacological Sciences, 2016, 20, 2630-3.	0.7	20
63	A rare cause of shortness of breath: relaxatio diaphragmatica. Internal and Emergency Medicine, 2015, 10, 1031-1032.	2.0	1
64	Identification and Management of Alcohol Withdrawal Syndrome. Drugs, 2015, 75, 353-365.	10.9	127
65	Social phobia and quality of life in morbidly obese patients before and after bariatric surgery. Journal of Affective Disorders, 2015, 179, 95-100.	4.1	11
66	Relationship Between the Thyroid Axis and Alcohol Craving. Alcohol and Alcoholism, 2015, 50, 24-29.	1.6	19
67	GABA _B Agonists for the Treatment of Alcohol Use Disorder. Current Pharmaceutical Design, 2015, 21, 3367-3372.	1.9	28
68	Pharmacological management of alcohol dependence: From mono-therapy to pharmacogenetics and beyond. European Neuropsychopharmacology, 2014, 24, 181-191.	0.7	30
69	Liver Transplantation in Alcoholic Patients. Alcoholism: Clinical and Experimental Research, 2014, 38, 1799-1799.	2.4	2
70	Sodium oxybate in maintaining alcohol abstinence in alcoholic patients according to Lesch typologies: A pilot study. Journal of Psychopharmacology, 2014, 28, 23-30.	4.0	18
71	Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. Expert Opinion on Pharmacotherapy, 2014, 15, 245-257.	1.8	42
72	Sodium Oxybate in the Treatment of Alcohol Withdrawal Syndrome: A Randomized Double-Blind Comparative Study versus Oxazepam. The GATE 1 Trial. CNS Drugs, 2014, 28, 743-752.	5.9	26

#	Article	IF	Citations
73	Quality of life in a cohort of high-dose benzodiazepine dependent patients. Drug and Alcohol Dependence, 2014, 142, 105-109.	3.2	47
74	An 85-year-old man with acute-onset of confusion and dyspnea after a fall: a diagnostic challenge. Internal and Emergency Medicine, 2014, 9, 779-783.	2.0	1
75	Hypokalemia-induced pseudoischemic electrocardiographic changes and quadriplegia. American Journal of Emergency Medicine, 2014, 32, 286.e1-286.e4.	1.6	4
76	Pharmacotherapy of acute alcoholic hepatitis in clinical practice. World Journal of Gastroenterology, 2014, 20, 2159.	3.3	12
77	Management of Alcohol Dependence in Patients with Liver Disease. CNS Drugs, 2013, 27, 287-299.	5.9	87
78	Liver Transplantation in Alcoholic Patients: Impact of an Alcohol Addiction Unit Within a Liver Transplant Center. Alcoholism: Clinical and Experimental Research, 2013, 37, 1601-1608.	2.4	156
79	A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacology Biochemistry and Behavior, 2013, 103, 784-791.	2.9	66
80	Incidence of Upper Aerodigestive Tract Cancer After Liver Transplantation for Alcoholic Cirrhosis: A 10-Year Experience in an Italian Center. Transplantation Proceedings, 2013, 45, 2733-2735.	0.6	11
81	Alcohol addiction: toward a patient-oriented pharmacological treatment. Expert Opinion on Pharmacotherapy, 2013, 14, 2157-2160.	1.8	7
82	Authors' Reply to Rolland et al.: "Management of Alcohol Dependence in Patients with Liver Disease― CNS Drugs, 2013, 27, 865-866.	5.9	0
83	Baclofen in the treatment of persistent hiccup: a case series. International Journal of Clinical Practice, 2013, 67, 918-921.	1.7	22
84	Alcoholic cardiomyopathy. BMJ Case Reports, 2013, 2013, bcr2013201449-bcr2013201449.	0.5	1
85	Brugada electrocardiographic findings in an 80-year-old man. BMJ Case Reports, 2013, 2013, bcr2013010226-bcr2013010226.	0.5	2
86	Moderate Alcohol Administration: Oxidative Stress and Nutritional Status., 2013,, 83-88.		0
87	Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation. Neuropsychopharmacology, 2012, 37, 163-177.	5.4	74
88	Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addictive Behaviors, 2012, 37, 561-564.	3.0	65
89	Alcoholic Hepatitis and Liver Transplantation: The Good News and What to Do about It. Frontiers in Psychiatry, 2012, 2, 80.	2.6	2
90	Ghrelin system in alcoholâ€dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. Addiction Biology, 2012, 17, 452-464.	2.6	118

#	Article	IF	CITATIONS
91	Alcohol use disorders in the elderly: A brief overview from epidemiology to treatment options. Experimental Gerontology, 2012, 47, 411-416.	2.8	132
92	Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity. European Neuropsychopharmacology, 2011, 21, 450-456.	0.7	26
93	Alpe Adria report 2010 $\hat{a} \in \hat{c}$ conclusions and recommendations for the treatment of alcohol dependence. Frontiers in Psychiatry, 2011, 2, 58.	2.6	1
94	Fecal calprotectin concentrations in alcoholic patients. European Journal of Gastroenterology and Hepatology, 2011, 23, 76-80.	1.6	7
95	Role of Feeding-Related Pathways in Alcohol Dependence: A Focus on Sweet Preference, NPY, and Ghrelin. Alcoholism: Clinical and Experimental Research, 2011, 35, 194-202.	2.4	66
96	Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease. Human Psychopharmacology, 2011, 26, 554-559.	1.5	30
97	Response to Ameisen. Alcohol and Alcoholism, 2011, 46, 504-505.	1.6	1
98	Dose-Response Effect of Baclofen in Reducing Daily Alcohol Intake in Alcohol Dependence: Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. Alcohol and Alcoholism, 2011, 46, 312-317.	1.6	173
99	Brain Tumors: Quality of Life. , 2011, , 295-301.		0
100	Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver International, 2010, 30, 867-870.	3.9	40
101	Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update. European Journal of Gastroenterology and Hepatology, 2010, 22, 779-786.	1.6	13
102	Turning the Clock Ahead: Potential Preclinical and Clinical Neuropharmacological Targets for Alcohol Dependence. Current Pharmaceutical Design, 2010, 16, 2159-2181.	1.9	31
103	Editorial: Pharmacotherapy of Alcohol Dependence: Past, Present and Future Research. Current Pharmaceutical Design, 2010, 16, 2074-2075.	1.9	7
104	In Response:. Journal of Clinical Gastroenterology, 2010, 44, 592-593.	2.2	1
105	Role of Trait Anxiety in Persistent Radicular Pain After Surgery for Lumbar Disc Herniation. Neurosurgery, 2010, 67, 265-271.	1.1	31
106	New advances in addiction medicine. Frontiers in Psychiatry, 2010, 1, 4.	2.6	2
107	Psychosocial findings in alcohol-dependent patients before and after three months of total alcohol abstinence. Frontiers in Psychiatry, 2010, 1, 17.	2.6	3
108	Effectiveness and Safety of Baclofen in the Treatment of Alcohol Dependent Patients. CNS and Neurological Disorders - Drug Targets, 2010, 9, 33-44.	1.4	104

#	Article	IF	Citations
109	Pregabalin similar to lorazepam for alcohol withdrawal symptoms. Evidence-Based Medicine, 2010, 15, 73-73.	0.6	6
110	Safety and Efficacy of Baclofen in the Treatment of Alcohol-Dependent Patients. Current Pharmaceutical Design, 2010, 16, 2113-2117.	1.9	86
111	Physical Considerations for Treatment Complications of Alcohol and Drug Use and Misuse. , 2010, , 1115-1145.		1
112	Beer Affects Oxidative Stress Due to Ethanol: A Preclinical and Clinical Study., 2009,, 459-466.		1
113	The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opinion on Investigational Drugs, 2009, 18, 675-686.	4.1	63
114	Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study. Journal of Psychopharmacology, 2009, 23, 883-890.	4.0	38
115	Is Cortisol Involved in the Alcohol-Related Fat Mass Impairment? A Longitudinal Clinical Study. Alcohol and Alcoholism, 2009, 44, 211-215.	1.6	20
116	Phytotherapeutic approach to alcohol dependence: New old way?. Phytomedicine, 2009, 16, 638-644.	5. 3	17
117	Link between insulin and metabolic disorders in cancer: does leptin play a key role?. Breast Cancer Research and Treatment, 2009, 115, 435-436.	2.5	0
118	Hormones and drinking behaviour: New findings on ghrelin, insulin, leptin and volumeâ€regulating hormones. An ESBRA Symposium report. Drug and Alcohol Review, 2009, 28, 160-165.	2.1	25
119	Understanding and Treating Patients With Alcoholic Cirrhosis: An Update. Alcoholism: Clinical and Experimental Research, 2009, 33, 1136-1144.	2.4	25
120	Role of the GABAB receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. Alcohol, 2009, 43, 559-563.	1.7	46
121	Celiac disease: from gluten to skin. Expert Review of Clinical Immunology, 2009, 5, 789-800.	3.0	12
122	Increased Serum High-density Lipoprotein-Cholesterol Concentration in Celiac Disease After Gluten-free Diet Treatment Correlates With Body Fat Stores. Journal of Clinical Gastroenterology, 2009, 43, 946-949.	2.2	47
123	Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study. Alcohol, 2008, 42, 375-381.	1.7	36
124	Elastography assessment in patients with chronic HCV infection. International Journal of Clinical Practice, 2008, 62, 1108-1112.	1.7	13
125	State and trait anxiety and depression in patients affected by gastrointestinal diseases: psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting. International Journal of Clinical Practice, 2008, 62, 1063-1069.	1.7	120
126	Insulin But Not Insulin Growth Factorâ€1 Correlates With Craving in Currently Drinking Alcoholâ€Dependent Patients. Alcoholism: Clinical and Experimental Research, 2008, 32, 450-458.	2.4	43

#	Article	IF	CITATIONS
127	Relationship Between the Hypothalamic–Pituitary–Thyroid Axis and Alcohol Craving in Alcoholâ€Dependent Patients: A Longitudinal Study. Alcoholism: Clinical and Experimental Research, 2008, 32, 2047-2053.	2.4	38
128	Effects of short-term moderate alcohol administration on oxidative stress and nutritional status in healthy males. Appetite, 2008, 50, 50-56.	3.7	33
129	Acute alcohol intoxication. European Journal of Internal Medicine, 2008, 19, 561-567.	2.2	270
130	An open randomized study of the treatment of escitalopram alone and combined with \hat{l}^3 -hydroxybutyric acid and naltrexone in alcoholic patients. Pharmacological Research, 2008, 57, 312-317.	7.1	27
131	Social phobia in coeliac disease. Scandinavian Journal of Gastroenterology, 2008, 43, 410-415.	1.5	47
132	Metabolic and Nutritional Features in Adult Celiac Patients. Digestive Diseases, 2008, 26, 128-133.	1.9	32
133	Intestinal Malabsorption and Skin Diseases. Digestive Diseases, 2008, 26, 167-174.	1.9	14
134	Affective and Psychiatric Disorders in Celiac Disease. Digestive Diseases, 2008, 26, 140-148.	1.9	37
135	Invited Commentary * Serotonin transporter (SERT) brain density and neurobiological cloninger subtypes model: a lesson by human autoradiography studies. Alcohol and Alcoholism, 2008, 43, 148-150.	1.6	17
136	Celiac Disease. New England Journal of Medicine, 2008, 358, 747-749.	27.0	8
137	Improvement of Physical Health and Quality of Life of Alcohol-Dependent Individuals With Topiramate Treatment <subtitle>US Multisite Randomized Controlled Trial</subtitle> . Archives of Internal Medicine, 2008, 168, 1188.	3.8	109
138	State and trait anxiety and depression in patients with primary brain tumors before and after surgery: 1-year longitudinal study. Journal of Neurosurgery, 2008, 108, 281-286.	1.6	108
139	Subclinical Neurological Abnormalities in Patients With Celiac Disease: Are They Associated by Brain Hypoperfusion?. Journal of Pediatric Gastroenterology and Nutrition, 2008, 46, 470-470.	1.8	1
140	Superior vena cava thrombosis treated by angioplasty and stenting in a cirrhotic patient with peritoneovenous shunt. Annals of Thoracic and Cardiovascular Surgery, 2008, 14, 60-2.	0.8	4
141	Coeliac disease and hearing loss: Preliminary data on a new possible association. Scandinavian Journal of Gastroenterology, 2007, 42, 1209-1213.	1.5	23
142	Baclofen Suppresses Alcohol Intake and Craving for Alcohol in a Schizophrenic Alcohol-Dependent Patient. Journal of Clinical Psychopharmacology, 2007, 27, 319-320.	1.4	54
143	Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: An open randomised comparative study. European Neuropsychopharmacology, 2007, 17, 781-789.	0.7	53
144	Wilson's disease. Lancet, The, 2007, 369, 902.	13.7	10

#	Article	IF	CITATIONS
145	Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet, The, 2007, 370, 1915-1922.	13.7	611
146	Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Digestive and Liver Disease, 2007, 39, 1071-1076.	0.9	64
147	Stress monitoring in a Guinness 10-day scuba dive. Laser Physics, 2007, 17, 448-452.	1.2	6
148	Analysis of the T1288R Mutation of the Wilson Disease ATP7B Gene in Four Generations of a Family: Possible Genotype-Phenotype Correlation with Hepatic Onset. Digestive Diseases and Sciences, 2007, 52, 2570-2575.	2.3	11
149	Coenzyme Q 10 and Cardiovascular Risk Factors in Idiopathic Sudden Sensorineural Hearing Loss Patients. Otology and Neurotology, 2007, 28, 878-883.	1.3	28
150	Primary renal angiosarcoma: A rare malignancy. A case report and review of the literaturea *†. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 307-312.	1.6	48
151	Complementary medicine for alcohol dependence in Italian services: A mail questionnaire. Complementary Therapies in Clinical Practice, 2006, 12, 216-221.	1.7	4
152	Baclofen in the Treatment of Alcohol Withdrawal Syndrome: A Comparative Study vs Diazepam. American Journal of Medicine, 2006, 119, 276.e13-276.e18.	1.5	173
153	Relationship Between Ghrelin Levels, Alcohol Craving, and Nutritional Status in Current Alcoholic Patients. Alcoholism: Clinical and Experimental Research, 2006, 30, 1933-1937.	2.4	154
154	Baclofen: a new drug for the treatment of alcohol dependence. International Journal of Clinical Practice, 2006, 60, 1003-1008.	1.7	63
155	A New Mutation of Wilson's Disease P-Type ATPase Gene in a Patient with Cirrhosis and Coombs-Positive Hemolytic Anemia. Digestive Diseases and Sciences, 2006, 51, 34-38.	2.3	8
156	Marked Decrease of Serum Ca 125 Levels After Denver Shunt Placement in a Patient With Cirrhosis and Refractory Ascites. Digestive Diseases and Sciences, 2006, 51, 1644-1646.	2.3	2
157	Genotype–phenotype correlation of the Wilson diseaseATP7B gene. American Journal of Medical Genetics, Part A, 2006, 140A, 933-933.	1.2	14
158	Suppression of Craving for \hat{l}^3 -Hydroxybutyric Acid by Naltrexone Administration. Clinical Neuropharmacology, 2005, 28, 87-89.	0.7	11
159	Baclofen-induced reduction of alcohol reinforcement in alcohol-preferring rats. Alcohol, 2005, 36, 161-168.	1.7	77
160	CELIAC DISEASE AND SKIN DISORDERS. Pediatric Dermatology, 2005, 22, 376-377.	0.9	2
161	Association between psoriasis and coeliac disease. British Journal of Dermatology, 2005, 152, 1393-1394.	1.5	11
162	Tolerance to baclofen?s sedative effect in alcohol-addicted patients: no dissipation after a period of abstinence. Psychopharmacology, 2005, 178, 351-352.	3.1	7

#	Article	IF	Citations
163	Anhedonia and Substance-Related Symptoms in Detoxified Substance-Dependent Subjects: A Correlation Study. Neuropsychobiology, 2005, 52, 37-44.	1.9	132
164	Psychological Support Counseling: A New Strategy to Increase Gluten-Free Diet Compliance in Celiac Patients. American Journal of Gastroenterology, 2005, 100, 1424-1425.	0.4	2
165	How Many Cravings? Pharmacological Aspects of Craving Treatment in Alcohol Addiction: A Review. Neuropsychobiology, 2005, 51, 59-66.	1.9	117
166	\hat{I}^3 -hydroxybutyrate as a treatment for alcoholism. Lancet, The, 2005, 366, 981-982.	13.7	55
167	Reduced plasma ghrelin concentration in celiac disease after gluten-free diet treatment. Scandinavian Journal of Gastroenterology, 2005, 40, 430-436.	1.5	39
168	Neurobiochemical and clinical aspects of craving in alcohol addiction: A review. Addictive Behaviors, 2005, 30, 1209-1224.	3.0	147
169	Baclofen: clinical data. , 2005, , 171-180.		1
170	Baclofen for outpatient treatment of alcohol withdrawal syndrome. Journal of Family Practice, 2005, 54, 24.	0.2	5
171	Gamma-hydroxybutyric acid. New England Journal of Medicine, 2005, 353, 1632-3.	27.0	0
172	Neurologic Disorders in Patients With Celiac Disease: Are They Mediated by Brain Perfusion Changes?. Pediatrics, 2004, 114, 1734-1734.	2.1	3
173	Gluten-related cerebral hypoperfusion and neurologic disorders in coeliac patients. Alimentary Pharmacology and Therapeutics, 2004, 20, 821-822.	3.7	2
174	Psychological support counselling improves glutenâ€free diet compliance in coeliac patients with affective disorders. Alimentary Pharmacology and Therapeutics, 2004, 20, 777-782.	3.7	90
175	Role of GABAB receptor in alcohol dependence: Reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotoxicity Research, 2004, 6, 403-414.	2.7	122
176	The Italian version of the Obsessive–Compulsive Drinking Scale: validation, comparison with the other versions, and difference between type 1- and type 2-like alcoholics. Drug and Alcohol Dependence, 2004, 74, 187-195.	3.2	86
177	Regional cerebral hypoperfusion in patients with celiac disease. American Journal of Medicine, 2004, 116, 312-317.	1.5	93
178	GAMMA-HYDROXYBUTYRIC ACID PLUS NALTREXONE IN THE TREATMENT OF ALCOHOLICS RESISTANT TO MONO-THERAPY Alcoholism: Clinical and Experimental Research, 2004, 28, 42A.	2.4	1
179	Evaluation of the albumin-gamma-glutamyltransferase isoenzyme as a diagnostic marker of hepatocellular carcinoma-complicating liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 288-295.	2.8	9
180	Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug and Alcohol Dependence, 2003, 70, 85-91.	3.2	113

#	Article	IF	CITATIONS
181	Association Between Migraine and Celiac Disease: Results From a Preliminary Case-Control and Therapeutic Study. American Journal of Gastroenterology, 2003, 98, 625-629.	0.4	135
182	Rapid Regression of Psoriasis in a Coeliac Patient after Gluten-Free Diet. Digestion, 2003, 68, 9-12.	2.3	57
183	Suppression of Alcohol Delirium Tremens by Baclofen Administration: A Case Report. Clinical Neuropharmacology, 2003, 26, 258-262.	0.7	56
184	BACLOFEN EFFICACY IN REDUCING ALCOHOL CRAVING AND INTAKE: A PRELIMINARY DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY. Alcohol and Alcoholism, 2002, 37, 504-508.	1.6	434
185	THE GABAB RECEPTOR AGONISTS BACLOFEN AND CGP 44532 PREVENT ACQUISITION OF ALCOHOL DRINKING BEHAVIOUR IN ALCOHOL-PREFERRING RATS. Alcohol and Alcoholism, 2002, 37, 499-503.	1.6	98
186	Rapid suppression of alcohol withdrawal syndrome by baclofen. American Journal of Medicine, 2002, 112, 226-229.	1.5	131
187	High Prevalence of Antiendothelial Cell Antibodies in Migraine. Headache, 2002, 42, 385-386.	3.9	6
188	Metadoxine in Acute Alcohol Intoxication: A Double-Blind, Randomized, Placebo-Controlled Study. Alcoholism: Clinical and Experimental Research, 2002, 26, 340-346.	2.4	58
189	Metadoxine in acute alcohol intoxication: a double-blind, randomized, placebo-controlled study. Alcoholism: Clinical and Experimental Research, 2002, 26, 340-6.	2.4	14
190	Gender affects reperfusion injury in rat liver. Digestive Diseases and Sciences, 2001, 46, 1305-1312.	2.3	28
191	Oxygen free radical production in rat liver: dose-related effect of ethanol on reperfusion injury. Digestive Diseases and Sciences, 2001, 46, 1057-1066.	2.3	16
192	Effect of a vegetable-protein-rich polymeric diet treatment on body composition and energy metabolism in inactive Crohn $\hat{E}\frac{1}{4}$ s disease. European Journal of Gastroenterology and Hepatology, 2000, 12, 5-11.	1.6	6
193	Gamma-hydroxybutyric acid Efficacy, potential abuse, and dependence in the treatment of alcohol addiction. Alcohol, 2000, 20, 217-222.	1.7	91
194	Ability of Baclofen in Reducing Alcohol Intake and Withdrawal Severity: I-Preclinical Evidence. Alcoholism: Clinical and Experimental Research, 2000, 24, 58-66.	2.4	175
195	Ability of Baclofen in Reducing Alcohol Craving and Intake: II-Preliminary Clinical Evidence. Alcoholism: Clinical and Experimental Research, 2000, 24, 67-71.	2.4	147
196	Changes in body composition, substrate oxidation, and resting metabolic rate in adult celiac disease patients after a 1-y gluten-free diet treatment. American Journal of Clinical Nutrition, 2000, 72, 76-81.	4.7	69
197	Low-serum high-density lipoprotein-cholesterol concentration as a sign of celiac disease. American Journal of Gastroenterology, 2000, 95, 3331-3332.	0.4	27
198	Serum leptin levels in post-hepatitis liver cirrhosis. Journal of Hepatology, 2000, 33, 38-42.	3.7	43

#	Article	IF	CITATIONS
199	Ability of Baclofen in Reducing Alcohol Intake and Withdrawal Severity: 1???Preclinical Evidence. Alcoholism: Clinical and Experimental Research, 2000, 24, 58-66.	2.4	16
200	Ability of Baclofen in Reducing Alcohol Craving and Intake: II???Preliminary Clinical Evidence. Alcoholism: Clinical and Experimental Research, 2000, 24, 67-71.	2.4	15
201	Nutritional status and energy metabolism in Crohn disease. American Journal of Clinical Nutrition, 1999, 69, 339-341.	4.7	2
202	Glucose metabolism and insulin sensitivity in inactive inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 1999, 13, 209-217.	3.7	30
203	Gammaâ€Hydroxybutyric Acid (GHB) in the Treatment of Alcohol Withdrawal Syndrome: A Randomized Comparative Study Versus Benzodiazepine. Alcoholism: Clinical and Experimental Research, 1999, 23, 1596-1604.	2.4	117
204	Nutritional Status and Body Fluid Distribution in Chronic Alcoholics Compared With Controls. Alcoholism: Clinical and Experimental Research, 1999, 23, 1232-1237.	2.4	32
205	A new HPLC method for the direct analysis of triglycerides of dicarboxylic acids in biological samples. Clinica Chimica Acta, 1999, 289, 11-21.	1.1	12
206	Long-term administration of GHB does not affect muscular mass in alcoholics. Life Sciences, 1999, 65, PL191-PL196.	4.3	23
207	Multivariate identification of metabolic features in inflammatory bowel disease. Metabolism: Clinical and Experimental, 1999, 48, 952-956.	3.4	17
208	State and trait anxiety in women affected by allergic and vasomotor rhinitis. Journal of Psychosomatic Research, 1999, 46, 283-289.	2.6	149
209	A Case of Gamma-Hydroxybutyric Acid Withdrawal Syndrome During Alcohol Addiction Treatment. Clinical Neuropharmacology, 1999, 22, 60-62.	0.7	54
210	Beer affects oxidative stress due to ethanol in rats. Digestive Diseases and Sciences, 1998, 43, 1332-1338.	2.3	27
211	Investigation into the Use of Alcohol at Thermal Spas: Can a Spa Represent a Place for Primary Prevention?. Alcoholism: Clinical and Experimental Research, 1998, 22, 1072-1073.	2.4	1
212	A case of marked cerebellar atrophy in a woman with anorexia nervosa and cerebral atrophy and a review of the literature., 1998, 24, 443-447.		19
213	Metabolic features of inflammatory bowel disease in a remission phase of the disease activity. Journal of Internal Medicine, 1998, 243, 339-347.	6.0	72
214	Influence of chronic alcohol abuse on body weight and energy metabolism: is excess ethanol consumption a risk factor for obesity or malnutrition?. Journal of Internal Medicine, 1998, 244, 387-395.	6.0	120
215	Î ³ -Hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients. Drug and Alcohol Dependence, 1998, 53, 7-10.	3.2	89
216	Maintaining abstinence from alcohol with \hat{I}^3 -hydroxybutyric acid. Lancet, The, 1998, 351, 38.	13.7	54

#	Article	IF	CITATIONS
217	Effect of disease localization on the anthropometric and metabolic features of Crohn's disease. American Journal of Gastroenterology, 1998, 93, 2411-2419.	0.4	54
218	Metabolic Features and Nutritional Status in Chronic Alcoholics. American Journal of Gastroenterology, 1998, 93, 665-666.	0.4	9
219	Three months of abstinence from alcohol normalizes energy expenditure and substrate oxidation in alcoholics: a longitudinal study. American Journal of Gastroenterology, 1998, 93, 2476-2481.	0.4	34
220	A case of marked cerebellar atrophy in a woman with anorexia nervosa and cerebral atrophy and a review of the literature. International Journal of Eating Disorders, 1998, 24, 443-447.	4.0	1
221	Gamma-hydroxybutyric acid in the treatment of alcohol dependence: possible craving development for the drug. Addiction, 1997, 92, 1035-1036.	3.3	25
222	Splenic Function and Alcohol Addiction. Alcoholism: Clinical and Experimental Research, 1997, 21, 197-200.	2.4	13
223	Manageability and Tolerability of gamma-Hydroxybutyric Acid in the Medium Term Outpatient Treatment of Alcoholism. Alcoholism: Clinical and Experimental Research, 1997, 21, 380-380.	2.4	9
224	Energy Expenditure, Substrate Oxidation, and Body Composition in Subjects with Chronic Alcoholism: New Findings from Metabolic Assessment. Alcoholism: Clinical and Experimental Research, 1997, 21, 962-967.	2.4	56
225	Absence of Hepatitis G Virus Infection in Patients with Alcoholic Cirrhosis. Alcoholism: Clinical and Experimental Research, 1997, 21, 1347-1347.	2.4	1
226	Prenatal exposure to ethanol in rats: Effects on liver energy level and antioxidant status in mothers, fetuses, and newborns. Alcohol, 1997, 14, 569-573.	1.7	38
227	Posatirelin for the treatment of degenerative and vascular dementia: results of explanatory and pragmatic efficacy analyses. Archives of Gerontology and Geriatrics, 1997, 26, 33-47.	3.0	6